New Immunological Therapeutic Strategies in Kidney Disease
A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 77
Special Issue Editor
Interests: exosome; extracelular vesicule; intracelllar comminication; immune tolerance; vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A new FDA-approved immunotherapy stabilizes kidney function in patients with IgA nephritis by suppressing intestinal immune system overactivity. In addition, targeting the IL-23/IL-17 pathway has shown promise in treating immune-mediated kidney diseases. Blocking IL-23 signaling in renal tubular epithelial cells can create an immune regulatory microenvironment in the kidney, effectively treating renal autoimmune disease. Also, chimeric antigen receptor (CAR) T-cell therapy is being adapted for kidney diseases. This approach can target autoreactive immune cells or restore immune tolerance. Furthermore, mesenchymal stem cells are being investigated for their potential to modulate chronic kidney disease progression through immunomodulatory, anti-fibrotic, anti-inflammatory, antioxidant, anti-apoptotic, and angiogenic properties. These emerging strategies represent a shift towards more targeted and personalized approaches for treating immune-mediated kidney diseases, potentially offering improved outcomes for patients with various renal conditions.
Dr. Yasunari Matsuzaka
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- IgA nephritis
- IL-23/IL-17 pathway
- CAR T-cell therapy
- mesenchymal stem cells
- innate lymphoid cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
